Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giuseppe Tonini

Showing results (1-10 of 406) with videos related to

Pageof 41
Sort By:
Expert Opinion on Investigational Drugs|April 21, 2015
Trends in the early investigational drug development and areas for improvementGiuseppe Tonini
ESMO Open|May 14, 2020
Brief letter of a doctor to his psychologist in the COVID-19 outbreak eraDaniele Santini, Giuseppe Tonini
The New England Journal of Medicine|March 11, 2016
Treatment of Advanced Renal-Cell CarcinomaDaniele Santini, Giuseppe Tonini
Current Cancer Drug Targets|January 22, 2010
Hormone-biological therapy in breast cancer: preclinical evidences, clinical studies and future directionsGaia Schiavon, Giuseppe Tonini
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2005
Thymidylate synthase expression in colorectal cancer: the never-ending storyBruno Vincenzi, Daniele Santini, Giuseppe Tonini
Expert Opinion on Pharmacotherapy|March 10, 2011
Bisphosphonate anticancer activityGiuseppe Tonini, Bruno Vincenzi, Daniele Santini
Women'S Health (London, England)|October 7, 2009
Will trastuzumab change the optimal adjuvant systemic therapy of patients with HER2-positive breast cancer?Daniele Santini, Bruno Vincenzi, Giuseppe Tonini
Nature Clinical Practice. Oncology|May 1, 2008
Updated follow-up of patients treated with bortezomib for relapsed multiple myelomaDaniele Santini, Bruno Vincenzi, Giuseppe Tonini
Women'S Health (London, England)|October 7, 2009
Taxanes in adjuvant chemotherapy for early breast cancerBruno Vincenzi, Daniele Santini, Giuseppe Tonini
Expert Opinion on Pharmacotherapy|May 14, 2008
Biological interaction between anti-epidermal growth factor receptor agent cetuximab and magnesiumBruno Vincenzi, Daniele Santini, Giuseppe Tonini
Pageof 41

Showing results (1-10 of 406) with videos related to

Sort By:
Pageof 41
Expert Opinion on Investigational Drugs|April 21, 2015
Trends in the early investigational drug development and areas for improvementGiuseppe Tonini
ESMO Open|May 14, 2020
Brief letter of a doctor to his psychologist in the COVID-19 outbreak eraDaniele Santini, Giuseppe Tonini
The New England Journal of Medicine|March 11, 2016
Treatment of Advanced Renal-Cell CarcinomaDaniele Santini, Giuseppe Tonini
Current Cancer Drug Targets|January 22, 2010
Hormone-biological therapy in breast cancer: preclinical evidences, clinical studies and future directionsGaia Schiavon, Giuseppe Tonini
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2005
Thymidylate synthase expression in colorectal cancer: the never-ending storyBruno Vincenzi, Daniele Santini, Giuseppe Tonini
Expert Opinion on Pharmacotherapy|March 10, 2011
Bisphosphonate anticancer activityGiuseppe Tonini, Bruno Vincenzi, Daniele Santini
Women'S Health (London, England)|October 7, 2009
Will trastuzumab change the optimal adjuvant systemic therapy of patients with HER2-positive breast cancer?Daniele Santini, Bruno Vincenzi, Giuseppe Tonini
Nature Clinical Practice. Oncology|May 1, 2008
Updated follow-up of patients treated with bortezomib for relapsed multiple myelomaDaniele Santini, Bruno Vincenzi, Giuseppe Tonini
Women'S Health (London, England)|October 7, 2009
Taxanes in adjuvant chemotherapy for early breast cancerBruno Vincenzi, Daniele Santini, Giuseppe Tonini
Expert Opinion on Pharmacotherapy|May 14, 2008
Biological interaction between anti-epidermal growth factor receptor agent cetuximab and magnesiumBruno Vincenzi, Daniele Santini, Giuseppe Tonini
Pageof 41